Duchenne Muscular Dystrophy Drugs Market Size to Reach US$ 4.00 Billion by 2028

Industry Overview of Duchenne Muscular Dystrophy Drugs Market
IMARC Group, a leading market research company, has recently releases report titled "Duchenne Muscular Dystrophy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028." The study provides a detailed analysis of the industry, including the global duchenne muscular dystrophy drugs market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Duchenne muscular dystrophy (DMD) drugs are used to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that mainly affects the male population and rarely females. The symptoms of this disease include difficulty walking, standing, and sitting, and speech difficulties, which can result in progressive weakness and loss, also called as atrophy, in the skeletal and heart muscles. The Duchenne muscular dystrophy drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Consequently, most of the drugs for the treatment of DMD are dystrophin-based.

How Big Is the Duchenne Muscular Dystrophy Drugs Market?
The global Duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.00 Billion by 2028, exhibiting a growth rate (CAGR) of 11.41% during 2023-2028.

Request for a PDF sample of this report:
https://www.imarcgroup.com/duchenne-muscular-dystrophy-drugs-market/requestsample

What Are the Growth Prospects and Trends in The Duchenne Muscular Dystrophy Drugs Industry?
The growing number of new product approvals and launches by the key manufacturers, on account of the increasing incidences of this disorder among consumers, is primarily driving the Duchenne muscular dystrophy drugs market. Furthermore, the rising clinical trials and the presence of a strong pipeline of items are also augmenting the market growth. Apart from this, the introduction of mutation-specific therapies, owing to continuous innovations in diagnostics, is positively influencing the global market. Moreover, extensive research and development (R&D) activities focusing on the proper detection and treatment of DMD for underserved categories, such as infants, females, and non-ambulant patients, are further bolstering the market growth. Besides this, the launch of favorable government initiatives providing good reimbursement policies and promoting target-specific treatments is acting as another significant growth-inducing factor. Additionally, rising urbanization levels and continuous improvements in medical infrastructure are also catalyzing the global market. In addition to this, the emerging product premiumization trend and inflating disposable incomes of the masses are expected to drive the Duchenne muscular dystrophy drugs market in the coming years.

What Is Included In Market Segmentation?
The report has been segmented the market into following categories:
Product Type Insights:
• Corticosteroids
o Prednisolone
o Prednisone
o Deflazacort
• Pain Management Drugs

Therapeutic Approach Insights:
• Mutation Suppression
• Exon Skipping
• Steroid Therapy

End User Insights:
• Hospitals
• Clinics
• Home Care Settings

Regional Insights:
• North America
o United States
o Canada
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Others
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Others
• Latin America
o Brazil
o Mexico
o Others
• Middle East and Africa

Ask Analyst for 10% free customized report:
https://www.imarcgroup.com/request?type=report&id=6715&flag=C

The report provides a comprehensive analysis of the industry key players listed below:
FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc.

Contact us:
IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: sales@imarcgroup.com Tel No:(D) +91 120 433 0800 Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.